LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial

IF 4 2区 医学 Q2 ALLERGY
Kai Guan, Shuang Liu, Yan Feng, Lisha Li, Xiaoming Zhu, Nai-Chau-Sun Bill, Haili Ma, Jie Yang, Cuicui Han, Heng Liu, Qingyu Wei, Haiyun Shi, Xueyan Wang
{"title":"LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial","authors":"Kai Guan,&nbsp;Shuang Liu,&nbsp;Yan Feng,&nbsp;Lisha Li,&nbsp;Xiaoming Zhu,&nbsp;Nai-Chau-Sun Bill,&nbsp;Haili Ma,&nbsp;Jie Yang,&nbsp;Cuicui Han,&nbsp;Heng Liu,&nbsp;Qingyu Wei,&nbsp;Haiyun Shi,&nbsp;Xueyan Wang","doi":"10.1002/clt2.70074","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Anti-IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP-003, a novel anti-IgE antibody, is being tested as an add-on treatment for SAR. This trial aimed to evaluate whether LP-003 is effective and safe for SAR.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This placebo-controlled double-blind phase 2 randomized clinical trial was conducted in 17 hospitals in China. SAR patients whose symptoms were inadequately controlled despite first-line treatment (nasal corticosteroids with or without oral antihistamine) in the previous two seasons were enrolled between July 6, 2023 and August 7, 2023. Participants were randomized in a ratio of 2:4:3 to receive subcutaneous injections of 100 mg LP-003, 200 mg LP-003 or placebo every 4 weeks for 2 doses. All patients received fluticasone propionate as standard-of-care (SoC). The main outcome was the mean total nasal symptom score (TNSS) during the peak pollen period (PPP). Secondary endpoints included a series of symptom and medication scores, quality of life assessments during PPP and pollen period (PP), immunogenicity and safety.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 180 participants were randomly assigned. The LP-003 + SoC treatment achieved a significantly lower TNSS compared with placebo + SoC (3.31 vs. 4.06, intergroup difference = −0.74, <i>p</i> = 0.0464). For key secondary outcomes, the LP-003 group also achieved significantly lower daily nasal symptom and rescue medication use scores (3.54 vs. 4.42, intergroup difference = −0.88, <i>p</i> = 0.0352), and daily ocular symptom and rescue medication use scores (1.66 vs. 2.19, intergroup difference = −0.54, <i>p</i> = 0.0245) compared to the placebo group. The suppression of free IgE was prevalent and persistent. There was no statistically significant difference in adverse events and severe adverse events between LP-003 and placebo groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These findings support LP-003 as a promising add-on option to the SoC for patients with moderate to severe SAR. Fixed dosage regimen and extensive suppression of free-IgE render it a cutting-edge advantage.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 6","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70074","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70074","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Anti-IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP-003, a novel anti-IgE antibody, is being tested as an add-on treatment for SAR. This trial aimed to evaluate whether LP-003 is effective and safe for SAR.

Methods

This placebo-controlled double-blind phase 2 randomized clinical trial was conducted in 17 hospitals in China. SAR patients whose symptoms were inadequately controlled despite first-line treatment (nasal corticosteroids with or without oral antihistamine) in the previous two seasons were enrolled between July 6, 2023 and August 7, 2023. Participants were randomized in a ratio of 2:4:3 to receive subcutaneous injections of 100 mg LP-003, 200 mg LP-003 or placebo every 4 weeks for 2 doses. All patients received fluticasone propionate as standard-of-care (SoC). The main outcome was the mean total nasal symptom score (TNSS) during the peak pollen period (PPP). Secondary endpoints included a series of symptom and medication scores, quality of life assessments during PPP and pollen period (PP), immunogenicity and safety.

Results

A total of 180 participants were randomly assigned. The LP-003 + SoC treatment achieved a significantly lower TNSS compared with placebo + SoC (3.31 vs. 4.06, intergroup difference = −0.74, p = 0.0464). For key secondary outcomes, the LP-003 group also achieved significantly lower daily nasal symptom and rescue medication use scores (3.54 vs. 4.42, intergroup difference = −0.88, p = 0.0352), and daily ocular symptom and rescue medication use scores (1.66 vs. 2.19, intergroup difference = −0.54, p = 0.0245) compared to the placebo group. The suppression of free IgE was prevalent and persistent. There was no statistically significant difference in adverse events and severe adverse events between LP-003 and placebo groups.

Conclusions

These findings support LP-003 as a promising add-on option to the SoC for patients with moderate to severe SAR. Fixed dosage regimen and extensive suppression of free-IgE render it a cutting-edge advantage.

Abstract Image

LP-003,一种用于控制不充分的季节性变应性鼻炎的新型高亲和力抗ige抗体:一项多中心、随机、双盲、安慰剂对照的2期临床试验
背景:抗ige治疗可作为控制不充分的季节性变应性鼻炎(SAR)患者的一种选择。LP-003是一种新型抗ige抗体,正在作为SAR的附加治疗进行测试。该试验旨在评估LP-003对SAR的有效性和安全性。方法该安慰剂对照双盲2期随机临床试验在中国17家医院进行。在2023年7月6日至2023年8月7日期间入组的前两个季节中,尽管接受了一线治疗(鼻皮质类固醇加或不加口服抗组胺药),但症状仍未得到充分控制的SAR患者。参与者以2:4:3的比例随机接受皮下注射100mg LP-003、200mg LP-003或安慰剂,每4周注射2次。所有患者均接受丙酸氟替卡松作为标准治疗(SoC)。主要观察指标为花粉高峰期鼻症状平均总分(TNSS)。次要终点包括一系列症状和药物评分、PPP和花粉期(PP)的生活质量评估、免疫原性和安全性。结果随机抽取180名受试者。LP-003 + SoC治疗的TNSS显著低于安慰剂+ SoC (3.31 vs 4.06,组间差异= - 0.74,p = 0.0464)。对于关键的次要结局,LP-003组的每日鼻症状和救援用药评分(3.54比4.42,组间差异= - 0.88,p = 0.0352)和每日眼部症状和救援用药评分(1.66比2.19,组间差异= - 0.54,p = 0.0245)也显著低于安慰剂组。游离IgE的抑制是普遍和持久的。LP-003组与安慰剂组在不良事件和严重不良事件方面无统计学差异。这些研究结果支持LP-003作为中重度SAR患者SoC的一个有希望的附加选择。固定的剂量方案和广泛抑制游离ige使其具有前沿优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信